Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors

PURPOSE: Ipatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in human cancers. The current study assessed the safety, tolerability, and pharmacokinetics of ipatasertib in Japanese patients with solid tumors. METHODS: This was a phase I, open-label, 3 + 3 dose-escalatio...

Descripción completa

Detalles Bibliográficos
Autores principales: Doi, Toshihiko, Fujiwara, Yutaka, Matsubara, Nobuaki, Tomomatsu, Junichi, Iwasa, Satoru, Tanaka, Akari, Endo-Tsukude, Chihiro, Nakagawa, Shintaro, Takahashi, Shunji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647215/
https://www.ncbi.nlm.nih.gov/pubmed/31227862
http://dx.doi.org/10.1007/s00280-019-03882-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6647215/
https://www.ncbi.nlm.nih.gov/pubmed/31227862
http://dx.doi.org/10.1007/s00280-019-03882-7

Ejemplares similares